Some Genuinely Good News on Price
After years of GLP-1s feeling out of reach for so many people, 2026 has brought a wave of competition that's finally pushing prices down. If cost has been your biggest barrier, this is the kind of news worth getting excited about — there are more affordable, legitimate options on the table now than ever before.
We've gathered the headline numbers and ranked them so you can quickly see where the deals are. Just remember: the lowest number on a chart isn't automatically your best choice, because eligibility, comfort, and format all matter. We'll help you weigh all of that.
Why Prices Are Falling
Competition is the engine here. New oral pills, branded subscriptions, and compounded products are all fighting for the same patients, and that pressure has dragged the whole market downward. The result is the widest range of legitimate price points the category has ever seen.
For you, more competition is simply good. It means manufacturers and providers are working to win your business with lower prices and easier access — a refreshing change from the days when there was essentially one expensive option.
Every Option, Ranked by Cost
From cheapest to priciest among the headline options: Foundayo at $25 with insurance leads the pack for eligible commercially insured patients. The $50 Medicare Bridge (arriving in July) comes next for eligible Part D enrollees. Compounded tirzepatide starts around $99 for cash-pay patients comfortable with a non-FDA-approved product.
Then Foundayo self-pay at $149, Wegovy subscriptions at $249, and Zepbound vials at $349 round out the FDA-approved options. That's a remarkable spread — from $25 to $349 — covering nearly every combination of insurance, diagnosis, and preference.
| Option | Approx. Cost/Month | Type |
|---|---|---|
| Foundayo (insured) | $25 | Oral, FDA-approved |
| Medicare Bridge (Jul 2026) | $50 | Eligible Part D |
| Compounded tirzepatide | $99 | Compounded |
| Foundayo (self-pay) | $149 | Oral, FDA-approved |
| Wegovy subscription | $249 | Injectable, FDA-approved |
| Zepbound vials | $349 | Injectable, FDA-approved |
2026 GLP-1 options by monthly cost (seed data — please verify before relying on it)
Picking the Right One for You
Here's the important nuance: the cheapest option on paper isn't always right for you. The $25 Foundayo price requires qualifying commercial insurance. The $50 Medicare Bridge requires Part D eligibility. The $99 compounded route requires comfort with a non-FDA-approved product. Each headline number has a 'who it's for' attached.
So instead of chasing the lowest figure, ask which option you actually qualify for and would be happy to stay on. Your insurance status, your diagnosis, your tolerance for compounded products, and your preference for pills versus injections all shape the real answer. Often the best deal is the cheapest one you genuinely qualify for and can sustain.
The Takeaway
The 2026 price war is great news for patients: legitimate GLP-1 options now span from $25 to $349, with something for nearly every situation. Falling prices mean cost is less of a dead end than it used to be.
Find your fit by matching eligibility and preference to the menu, not by reflexively grabbing the lowest number. And revisit it periodically — with prices still moving, an even better option may be just around the corner. Your prescriber can help you stay on the best deal for your situation.